memantine has been researched along with Conjugate Nystagmus in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis." | 9.14 | Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010) |
| "The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine." | 7.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "A prospective examiner-blind, cross-over study was conducted to compare the efficacy of memantine (40 or 60 mg/day) and gabapentin (1,200 mg/day) as therapy for acquired fixational pendular nystagmus (APN) in 11 patients with multiple sclerosis." | 5.14 | Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 2010) |
| "Memantine is a relatively new drug specially developed for use in moderate-to-severe dementia." | 4.82 | Memantine: pharmacological properties and clinical uses. ( Kumar, S, 2004) |
| "The authors retrospectively analysed Snellen visual acuity (VA), subjective visual function, and eye movement recordings of 23 patients with nystagmus (13 secondary to multiple sclerosis, three associated with other neurological diseases, two idiopathic infantile, and five with associated ocular diseases) treated with gabapentin or memantine." | 3.73 | The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. ( Gottlob, I; McLean, RJ; Proudlock, FA; Sarvananthan, N; Shery, T, 2006) |
| "The most common causes of acquired pendular nystagmus (APN) are multiple sclerosis (MS) and oculopalatal tremor (OPT), both of which result in poor visual quality of life." | 2.94 | Gabapentin and Memantine for Treatment of Acquired Pendular Nystagmus: Effects on Visual Outcomes. ( Abouaf, L; Berthiller, J; Colombet, B; Nerrant, E; Pollet-Villard, F; Tilikete, C; Vie, AL; Vighetto, A; Vukusic, S, 2020) |
| "Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen." | 2.48 | The pharmacological treatment of acquired nystagmus. ( Kennard, C; Mehta, AR, 2012) |
| "BACKGROUND Acquired pendular nystagmus (APN) is a back and forth, oscillatory eye movement in which the 2 oppositely directed slow phases have similar waveforms." | 1.72 | Pharmacological and Behavioral Strategies to Improve Vision in Acquired Pendular Nystagmus. ( Abegg, M; Brügger, D; Kerkeni, H; Mantokoudis, G; Zee, DS, 2022) |
| "Acquired pendular nystagmus (APN) occurs with multiple sclerosis (MS) and oculopalatal tremor (OPT); distinct features of the nystagmus have led to the development of separate models for their pathogenesis." | 1.37 | Pharmacological tests of hypotheses for acquired pendular nystagmus. ( Leigh, RJ; Optican, LM; Shaikh, AG; Thurtell, MJ, 2011) |
| "Acquired pendular nystagmus (APN) is regularly accompanied by oscillopsia and impairment of static visual acuity." | 1.30 | Drug therapy for acquired pendular nystagmus in multiple sclerosis. ( Albrecht, H; Dieterich, M; Pöllmann, W; Starck, M; Straube, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Kerkeni, H | 1 |
| Brügger, D | 1 |
| Mantokoudis, G | 1 |
| Abegg, M | 1 |
| Zee, DS | 1 |
| Kremmyda, O | 1 |
| Feil, K | 1 |
| Bardins, S | 1 |
| Strupp, M | 2 |
| Nerrant, E | 1 |
| Abouaf, L | 1 |
| Pollet-Villard, F | 1 |
| Vie, AL | 1 |
| Vukusic, S | 1 |
| Berthiller, J | 1 |
| Colombet, B | 1 |
| Vighetto, A | 1 |
| Tilikete, C | 1 |
| Kalla, R | 1 |
| Spiegel, R | 1 |
| Wagner, J | 1 |
| Rettinger, N | 1 |
| Jahn, K | 1 |
| Green, AJ | 1 |
| McLean, RJ | 2 |
| Gottlob, I | 2 |
| Starck, M | 2 |
| Albrecht, H | 2 |
| Pöllmann, W | 2 |
| Dieterich, M | 2 |
| Straube, A | 2 |
| Thurtell, MJ | 2 |
| Joshi, AC | 1 |
| Leone, AC | 1 |
| Tomsak, RL | 1 |
| Kosmorsky, GS | 1 |
| Stahl, JS | 1 |
| Leigh, RJ | 2 |
| Pieh-Beisse, C | 1 |
| Lagrèze, WA | 1 |
| Shaikh, AG | 1 |
| Optican, LM | 1 |
| Mehta, AR | 1 |
| Kennard, C | 1 |
| Kumar, S | 1 |
| Shery, T | 1 |
| Proudlock, FA | 1 |
| Sarvananthan, N | 1 |
4 reviews available for memantine and Conjugate Nystagmus
| Article | Year |
|---|---|
[Pharmacotherapy of central oculomotor disorders].
Topics: 4-Aminopyridine; Amifampridine; Amines; Baclofen; Cyclohexanecarboxylic Acids; Diagnosis, Differenti | 2008 |
The pharmacological treatment of nystagmus: a review.
Topics: Amines; Animals; Baclofen; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2009 |
The pharmacological treatment of acquired nystagmus.
Topics: Amines; Aminopyridines; Baclofen; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; | 2012 |
Memantine: pharmacological properties and clinical uses.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Dementia; Dementia, Vascular; Excitatory Amino Acid Antago | 2004 |
3 trials available for memantine and Conjugate Nystagmus
| Article | Year |
|---|---|
Gabapentin and Memantine for Treatment of Acquired Pendular Nystagmus: Effects on Visual Outcomes.
Topics: Adult; Cross-Over Studies; Excitatory Amino Acid Antagonists; Eye Movements; Female; Gabapentin; Hum | 2020 |
Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin.
Topics: Adult; Amines; Brain Stem; Clinical Protocols; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dose | 2010 |
Crossover trial of gabapentin and memantine as treatment for acquired nystagmus.
Topics: Adult; Amines; Cross-Over Studies; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; E | 2010 |
7 other studies available for memantine and Conjugate Nystagmus
| Article | Year |
|---|---|
Pharmacological and Behavioral Strategies to Improve Vision in Acquired Pendular Nystagmus.
Topics: Eye Movements; Female; Gabapentin; Humans; Memantine; Middle Aged; Nystagmus, Pathologic; Vision Dis | 2022 |
Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report.
Topics: Eye Movements; Humans; Memantine; Multiple Sclerosis; Nystagmus, Pathologic | 2023 |
Understanding pseudo: the symptoms are real, the cause is unclear.
Topics: Brain; Chemotaxis, Leukocyte; Clinical Trials as Topic; Encephalitis; Excitatory Amino Acid Antagoni | 2009 |
[Pharmacological treatment of nystagmus].
Topics: 4-Aminopyridine; Amines; Anticonvulsants; Baclofen; Cyclohexanecarboxylic Acids; Dopamine Agents; Ga | 2011 |
Pharmacological tests of hypotheses for acquired pendular nystagmus.
Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A | 2011 |
The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Gab | 2006 |
Drug therapy for acquired pendular nystagmus in multiple sclerosis.
Topics: Adult; Electrooculography; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middl | 1997 |